Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
McKesson
Moodys
Dow
Harvard Business School

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR COMETRIQ


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cometriq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01683994 ↗ Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Completed National Cancer Institute (NCI) Phase 1/Phase 2 2012-09-07 Background: - Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate tumors respond to it. Docetaxel and prednisone are standard treatments for advanced prostate cancer. Researchers want to see if adding cabozantinib to these two drugs can be a safe and effective treatment for this type of cancer. Objectives: - To test the safety and effectiveness of cabozantinib with standard treatments for advanced prostate cancer. Eligibility: - Individuals at least 18 years of age who have advanced prostate cancer that has not responded to standard treatments. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed. - Participants will receive the cancer drugs over 21-day cycles of treatment. They will take docetaxel and cabozantinib on day 1 of each cycle. Each docetaxel infusion will take about 1 hour. They will also take prednisone by mouth twice each day. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the study drugs for as long as their cancer does not worsen and side effects are not too severe.
NCT01688999 ↗ Cabozantinib for Advanced Urothelial Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2012-09-11 Background: - Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian tumors respond to it. Researchers want see if cabozantinib can be a safe and effective treatment for urothelial cancer. Objectives: - To test the safety and effectiveness of cabozantinib for advanced urothelial cancer. Eligibility: - Individuals at least 18 years of age who have advanced urothelial cancer that has not responded to standard treatments. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tumor tissue samples will also be collected. Imaging studies will also be performed. - Participants will take cabozantinib by mouth once per day on each day of a 28-day cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the study drug for as long as their cancer does not worsen and side effects are not too severe.
NCT01703065 ↗ Cabozantinib in Men With Castration-Resistant Prostate Cancer Terminated National Cancer Institute (NCI) Phase 2 2013-06-18 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01703065 ↗ Cabozantinib in Men With Castration-Resistant Prostate Cancer Terminated Prostate Cancer Foundation Phase 2 2013-06-18 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01703065 ↗ Cabozantinib in Men With Castration-Resistant Prostate Cancer Terminated University of Washington Phase 2 2013-06-18 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cometriq

Condition Name

Condition Name for Cometriq
Intervention Trials
Stage IV Renal Cell Cancer AJCC v8 4
Recurrent Malignant Solid Neoplasm 4
Stage III Renal Cell Cancer AJCC v8 3
Stage IV Renal Cell Cancer AJCC v7 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cometriq
Intervention Trials
Carcinoma 28
Carcinoma, Renal Cell 10
Neoplasms 9
Adenocarcinoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cometriq

Trials by Country

Trials by Country for Cometriq
Location Trials
United States 615
Canada 14
Japan 5
Germany 5
Belgium 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cometriq
Location Trials
California 27
Pennsylvania 23
Illinois 21
Ohio 21
Massachusetts 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cometriq

Clinical Trial Phase

Clinical Trial Phase for Cometriq
Clinical Trial Phase Trials
Phase 3 3
Phase 2 34
Phase 1/Phase 2 2
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cometriq
Clinical Trial Phase Trials
Recruiting 18
Active, not recruiting 15
Completed 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cometriq

Sponsor Name

Sponsor Name for Cometriq
Sponsor Trials
National Cancer Institute (NCI) 36
Exelixis 13
University of California, Irvine 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cometriq
Sponsor Trials
NIH 36
Other 22
Industry 16
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.